FOLH1 and posterior cortical atrophy: In this context, 68 Ga-labeled prostate-specific membrane antigen (PSMA) targeting PET/CT has demonstrated to localize PCa-related lesions with high sensitivity significantly impacting clinical decision making [8–13].